CTOs on the Move

Institute for Medical Research

www.imr.org

 
Institute for Medical Research is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.imr.org
  • 508 Fulton St
    Durham, NC USA 27705
  • Phone: 919.286.0411

Executives

Name Title Contact Details

Similar Companies

TVG-Medulla

TVG-Medulla, LLC (Medulla) is a wellness-focused healthcare management organization providing incomparable support and services to more than 40 Chiro One Wellness Center locations. In addition to our full-scale management departments and a wide-range of Medulla career opportunities, Medulla also offers engaging wellness programs and education services to communities, employers and organizations across Chicagoland.

Intervet/ Schering-Plough Animal Health

Intervet/ Schering-Plough Animal Health is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Outer Cape Health Services -Wellfleet Health Center

Outer Cape Health Services -Wellfleet Health Center is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Wellfleet, MA. To find more information about Outer Cape Health Services -Wellfleet Health Center, please visit www.outercape.org

Arise Healthcare

Arise Healthcare is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioSig Technologies

BioSig Technologies, Inc. (OTCQB: BSGM) is a medical device company that is developing a proprietary technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig`s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance for the PURE EP System.